Mila Ortigoza is an Infectious Disease physician affiliated with New York University. OpenAlex indexes 26 publications with 1,559 citations (h-index 10); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
550 1st Ave
Nyu Langone Medical Center
New York, NY 100166402
Telephone
212-263-5506Provider last certified this registry record 11 Nov 2020.
Clinical trials
- CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients
Sponsor: NYU Langone Health
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2019)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
59.8%ACE inhibitor19.5%Lisinopril100%Part D<11 patientsThiazide diuretic13.8%Hydrochlorothiazide100%Part D<11 patients+ 2 more classes in this area
Anti-infectives
27.6%Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor13.8%Isentress100%Part D<11 patientsHuman Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor13.8%Triumeq100%Part D<11 patientsMetabolism & gastrointestinal
12.6%Biguanide (metformin)12.6%Metformin Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2019–2023 per NIH RePORTER. The latest:
- Biology of Influenza Virus Transmission
New York University School of Medicine
FY2023$186,352K08AI141759 - Biology of Influenza Virus Transmission
New York University School of Medicine
FY2022$186,352K08AI141759 - Biology of Influenza Virus Transmission
New York University School of Medicine
FY2021$186,352K08AI141759
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- IFNγ-Driven Inflammatory Responses in the Nasal Mucosa Drive Influenza Virus Shedding and Transmission
bioRxiv (Cold Spring Harbor Laboratory)
2026
Similar KOLs
Other experts from the same institution or the same specialty.
Steven Galetta, MD
New York University
Herbert Lepor, MD
New York University
Aasma Shaukat, MD
New York University
Jerry Shapiro, MD
New York University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”